# Assess Feasibility of an Acellular Pertussis Vaccine (Pa) Given Soon After Birth, Followed by 3-dose Primary Vaccination With the DTPa-HBV-IPV/Hib Vaccine

> **NCT00289796** · PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 121 (actual)

## Conditions studied

- Hepatitis B

## Interventions

- **BIOLOGICAL:** DTPa-HBV-IPV/Hib

## Key facts

- **NCT ID:** NCT00289796
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-07
- **Primary completion:** 2006-04
- **Final completion:** 2006-12
- **Target enrollment:** 121 (ACTUAL)
- **Last updated:** 2017-02-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00289796

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00289796, "Assess Feasibility of an Acellular Pertussis Vaccine (Pa) Given Soon After Birth, Followed by 3-dose Primary Vaccination With the DTPa-HBV-IPV/Hib Vaccine". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00289796. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*